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The close functional relationship between p53 and the breast cancer susceptibility genes BRCA1 and BRCA2 has promoted the
investigation of various polymorphisms in the p53 gene as possible risk modifiers in BRCA1/2 mutation carriers. Specifically, two
polymorphisms in p53, c.97-147ins16bp and p.Arg72Pro have been analysed as putative breast cancer susceptibility variants, and it
has been recently reported that a p53 haplotype combining the absence of the 16-bp insertion and the presence of proline at codon
72 (No Ins-72Pro) was associated with an earlier age at the onset of the first primary tumour in BRCA2 mutation carriers in the
Spanish population. In this study, we have evaluated this association in a series of 2932 BRCA1/2 mutation carriers from the
Consortium of Investigators of Modifiers of BRCA1 and BRCA2.
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Given the involvement of p53 in cell cycle control, DNA repair
and apoptosis, the role of this gene in cancer susceptibility has
been extensively studied. Specifically, two polymorphisms in p53,
c.97-147ins16bp and p.Arg72Pro have been analysed as putative
breast cancer susceptibility variants, although not all studies have
yielded consistent results (Weston et al, 1997; Wang-Gohrke et al,
1998; Suspitsin et al, 2003; Damin et al, 2006; Baynes et al, 2007;
Costa et al, 2008). The Arg72Pro single-nucleotide polymorphism
(SNP) has gained special attention, as there is consistent evidence
of functional differences in apoptotic rates between the Arg and
Pro variants (Biros et al, 2002; Wu et al, 2002; Dumont et al, 2003).
In addition, the close functional relationship between p53 and the
breast cancer susceptibility genes BRCA1 and BRCA2 (Jonkers
et al, 2001; Ongusaha et al, 2003; Liu et al, 2007) has promoted the
investigation of the Arg72Pro SNP as a possible risk modifier
in BRCA1/2 mutation carriers (Martin et al, 2003). Indeed, it was
recently reported that a p53 haplotype combining the absence
of the 16-bp insertion and the presence of proline at codon 72
(No Ins-72Pro) was associated with an earlier age at onset of the
first primary tumour in BRCA2 mutation carriers in the Spanish
population (Osorio et al, 2006). In this study, we have evaluated
this association in a series of 2932 BRCA1/2 mutation carriers from Received 4 July 2007; accepted 30 July 2008
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sthe Consortium of Investigators of Modifiers of BRCA1 and BRCA2
(CIMBA) (Chenevix-Trench et al, 2007).
MATERIALS AND METHODS
Patients
A total of 2088 BRCA1 mutation carriers, 841 BRCA2 mutation
carriers and 3 carriers of mutations in both genes ascertained from
eight centres participating in CIMBA were included in this study
(Table 1). The inclusion criteria for subjects is described elsewhere
(Chenevix-Trench et al, 2007).
Genotyping
Genotypes for the two polymorphisms – Ins16bp and Arg72Pro –
were determined for each sample using previously described
methodology (Osorio et al, 2006). In some cases, the Ins16bp SNP
was genotyped by DHPLC on the WAVE HT system (Transge-
nomic, Omaha, NE, USA) using an acetonitrile gradient and
profiles analysed with the Navigatort software (Transgenomic),
and the Arg72Pro SNP was genotyped by Taqman (Applied
Biosystems, Foster City, CA, USA). Hardy–Weinberg equilibrium
(HWE) for each polymorphism was tested using the likelihood
ratio test among unrelated individuals. The German Consortium of
Hereditary Breast and Ovarian Cancer (GCHBOC) study gave
HWE P-values of 0.005 and 0.043 for Ins16bp and Arg72Pro,
respectively; therefore, all genotypes from that patient subset were
confirmed by an alternative technique (DHPLC). In addition,
individuals homozygous for Ins16bp were directly sequenced. The
concordance rate was 100% in both instances; accordingly, the
GCHBOC mutation carriers were included in all subsequent
analyses. Call rates ranged between 92 and 100% across studies.
Statistical analysis
Haplotypes were imputed using the R-package ‘hapassoc’ (Burkett
and McNeney, 2006). Associations of individual haplotypes with
time to breast cancer or ovarian cancer diagnosis were evaluated
using weighted Cox proportional hazards models, using age as the
time variable (Antoniou et al, 2005). Carriers were censored at the
first occurrence of breast or ovarian cancer or bilateral prophy-
lactic mastectomy. To allow for correlations between members of
the same family, Huber and White robust estimators of variance
were used, considering women clustered within families (Huber,
1967). The most frequent haplotype was taken as the reference and
all other haplotypes were included in the multivariate model
considering the number of copies of that particular variant. Models
were adjusted for ethnicity, birth cohort and centre of recruitment.
The analysis considered BRCA1 and BRCA2 mutation carriers
separately (Table 2) and all carriers combined (data not shown).
RESULTS AND DISCUSSION
Genotype distributions and frequencies for the Ins16bp and
Arg72Pro polymorphisms are shown in Table 1. Allele frequencies
were similar to those previously published (Osorio et al, 2006), and
genotype frequencies were consistent with HWE, except for the
carriers from GCHBOC (see Materials and Methods). Haplotypes
were inferred, and haplotype- and genotype-specific hazard ratios
were estimated separately for each of breast (Table 2) and ovarian
cancer (data not shown), among BRCA1 and BRCA2 mutation
carriers. No evidence of association was found for any of the
genotypes or haplotypes analysed with either breast or ovarian
cancer risk, including the No Ins-72Pro haplotype, previously
reported to be associated with an increased risk to develop a first
primary tumour before 35 years of age in BRCA2 mutation carriers
(Osorio et al, 2006).
To confirm that this negative result was not due to the different
analytic approach performed in this study, we carried out a logistic
regression analysis, as was done in the original study (Osorio et al,
2006), considering those with age at diagnosis younger than 35 as
cases, and did not find a positive association between early
diagnosis and this haplotype. In the original study, the result was
corroborated by a functional assay (Osorio et al, 2006), in which a
decrease in apoptotic rate was found to be associated with the No
Ins-72Pro haplotype. However, although concordant, both the
genetic and the functional studies were limited by the small sample
size (265 and 24 individuals, respectively), as reflected in the
marginal statistically significant results described in that report.
In summary, the previously reported association of the No Ins-
72Pro haplotype in p53 with an increased cancer risk in BRCA2
mutation carriers (Osorio et al, 2006) has not been validated in a
larger series proceeding from the Consortium of Investigators of
Modifiers of BRCA1 and BRCA2 (CIMBA). In this series of 2932
BRCA1/2 mutation carriers, no evidence of modification of breast
or ovarian cancer risk by any of the two polymorphisms, Ins16bp
and Arg72Pro, or their haplotype combinations has been detected.
The lack of confirmation of a previously reported association
found in a much smaller series highlights the necessity of
international collaborative efforts aimed at achieving the statistical
power required to reach reliable definitive conclusions in genetic
association studies.
Table 1 Genotype distribution of the two p53 polymorphisms in the BRCA1 and BRCA2 mutation carriers by participating study
Country of Ascertainment
Ins16bp N (%) Arg72Pro N (%)
Study residence basis No Ins No Ins/16bp Ins 16bpIns Total Arg72Arg Arg72Pro Pro72Pro Total
CNIO Spain and Greece
a Clinic 335 (74.12%) 105 (23.23%) 12 (2.65%) 452 281 (56.31%) 176 (35.27%) 42 (8.42%) 499
MBCSG Italy Clinic 190 (65.07%) 91 (31.16%) 11 (3.77%) 292 156 (50.81%) 135 (43.97%) 16 (5.21%) 307
DKFZ Germany, Pakistan,
Colombia
Clinic 128 (74.42%) 41 (23.84%) 3 (1.74%) 172 87 (51.18%) 67 (39.41%) 16 (9.41%) 170
GCHBOC
b Germany Clinic 593 (75.16%) 171 (21.67%) 25 (3.17%) 789 474 (56.97%) 294 (35.34%) 64 (7.69%) 832
HEBCS Finland Clinic 148 (78.72%) 39 (20.74%) 1 (0.53%) 188 96 (51.06%) 79 (42.02%) 13 (6.91%) 188
NCI United States Clinic 160 (73.06%) 56 (25.57%) 3 (1.37%) 219 96 (50.26%) 81 (42.41%) 14 (7.33%) 191
IHCC Poland Clinic 458 (67.25%) 202 (29.66% 21 (3.08%) 681 328 (48.16%) 289 (42.44%) 64 (9.40%) 681
Total 2012 (72.04%) 705 (25.24%) 76 (2.72%) 2793
c 1518 (52.93%) 1121 (39.09%) 229 (7.98%) 2869
Abbreviations: GCHBOC¼German Consortium of Hereditary Breast and Ovarian Cancer; HWE¼Hardy–Weinberg equilibrium.
aThe CNIO series consisted of samples from
the Spanish Consortium for the Study of Genetic Modifiers of BRCA1 and BRCA2 and the NCSR Demokritos, Athens (Greece). Cases from the original study were included in
the analysis (Osorio et al, 2006).
bDeviation from HWE with P-values of 0.005 and 0.043 was observed for Ins16bp and Arg72Pro, respectively.
cMissing genotypes are not
included in the totals. Owing to technical difficulties, more failed genotypes were observed for the Ins16bp polymorphism.
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